Aimmune Therapeutics stock surged ahead of market open Monday, after the FDA announced Friday it had approved Aimmune’s peanut allergy treatment for children. It’s the first such treatment to gain approval from the FDA. Shares jumped as much as 17% Monday morning. Visit Business Insider’s homepage for more stories. The […]
The US Food and Drug Administration has approved a drug that would mitigate allergic reactions to peanuts for children aged 4 to 17 years old. Palforzia comes in a powder form containing small amounts of peanut protein, which are administered in increasing doses until patients can tolerate the equivalent of […]
2019 could be the year of the first treatment for kids with peanut allergies. Two companies could compete for a market of around $US3 billion – though one, DBV Technologies, just hit a major roadblock The treatments aren’t a cure, but do reduce the risk of a dangerous allergic reaction […]
